Summary:
Do you have moderate to severe uncontrolled asthma?
Allergy and Asthma Associates Santa Clara Valley Research Center is conducting a 52 week randomized, double blind, parallel group, placebo-controlled study designed to evaluate efficacy and safety of a fixed 300 mg dose of Tralokinumab administered subcutaneously in subjects with uncontrolled asthma on inhaled corticosteroid plus long-acting B2-agonist and having a history of asthma exacerbations.
Qualified Participants Must:
• Be between 12 and 75 years of age
•
Have a weight of >40 and <150 kg
•
Have documented physician-diagnosed asthma for at least 12 months
•
Have documented 2 exacerbations in the past 12 months
Qualified Participants May Receive:
Compensation for time and travel as well as medication at no cost.